Vaxzevria significantly boosted antibody levels against Omicron

University of Oxford study supports use of Vaxzevria as third dose booster against Omicron Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant AstraZeneca’s Read More …

Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study

Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19 In this pre-clinical study, Evusheld’s Inhibitory Concentration 50 (IC50), a measure of neutralising potency of an antibody, was 171 ng/ml and 277 ng/ml in two confirmatory tests, which is within the Read More …